Promising cocktail targets tough pancreatic tumors

NCT ID NCT03563248

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding losartan (a blood pressure drug) and nivolumab (an immunotherapy) to standard chemotherapy and radiation can improve surgery outcomes for people with localized pancreatic cancer. About 168 participants with borderline resectable or locally advanced tumors will receive the combination. The main goal is to see if more tumors can be completely removed with clear margins.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
New York University Langone Medical Center

New York, New York, 10016, United States
Newton Wellesley Hospital

Newton, Massachusetts, 02462, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
The Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.